The importance of pH adjustment for preventing fibrin glue dissolution in the stomach: an in vitro study

Yoshitaka Takegawa1, Toshitatsu Takao2*, Hiroya Sakaguchi2, Tatsuya Nakai2, Kazuhiro Takeo3, Yoshinori Morita2, Takashi Toyonaga2 & Yuzo Kodama2

Combined use of fibrin glue and polyglycolic acid (PGA) sheets has attracted attention as a preventive measure for complications associated with endoscopic submucosal dissection. However, fibrin glue is a protein that may be dissolved by gastric acid. We evaluated the effect of artificial gastric acid on fibrin clot. The dissolution time of three layers of fibrin glue with PGA sheets was measured in five groups (pH 1.2, 2.0, 4.0, 5.5, and 6.0 with pepsin). Measurements of three samples per group were made. The mean number of the remaining layers at each measurement point was observed for 168 h. The time to complete dissolution of the three layers of fibrin gel in the three samples was 2.5 h at pH 1.2, 5 h at pH 2.0, 24 h at pH 4.0, and 48 h and 6 h at pH 5.5. In order to maintain fibrin glue in the stomach for a long period, there was a need to avoid pepsin activation secondary to acidification of gastric juice. The use of strong antacids is recommended.

The use of fibrin glue has been widely investigated in the field of gastrointestinal endoscopy. The treatment method of using fibrin glue and polyglycolic acid (PGA) sheets has recently attracted attention as a preventive method for complications related with gastric endoscopic submucosal dissection (ESD) or gastrointestinal fistula. In fact, some reports suggested the effectiveness of fibrin glue and PGA sheets in fixing ESD-related perforation or gastrointestinal fistula1–5 and in preventing delayed bleeding in patients taking antithrombotic drugs6–8. The use of fibrin glue as a preventive measure for post-ESD stenosis in the vicinity of the cardia of the stomach is under consideration9. Fibrin glue is very compatible with gastrointestinal endoscopy because of its ability to be delivered to the target site as a liquid and its high biocompatibility. Although it is expected to be used in a wide range of applications, the adhesion time of fibrin glue to the target site of the PGA sheet varies among cases. In a report by Fukuda et al., this adhesion time ranged from 1 to 32 days6. Because fibrin glue mainly comprises plasma-derived proteins, its use in the stomach carries the risk for dissolution by gastric acid; this may be one of the reasons for the variable effect of fibrin glue. Therefore, in this in vitro study, we investigated the effects of the protein-digesting enzyme pepsin and pH level on fibrin glue.

Materials and methods

A PGA sheet measuring 2.3 cm in diameter (NEOVEIL sheet 0.15, GUNZE LIMITED, Kyoto Japan) was placed on the bottom of a glass vial and fixed using fibrin glue (BOLHEAL®, KM Biologics Co., Ltd., Kumamoto Japan). Fibrin glue comprises two solutions (i.e., fibrinogen and thrombin); 0.25 mL of each solution was used to form a 1-mm-thick layer of fibrin glue containing a PGA sheet. This was repeated three times to form a total of three layers per vial. Artificial gastric juice with pepsin was prepared under different conditions of pH (pH 1.2, 2.0, 4.0, 5.5, and 6.0); these five groups in total were set up with reference to the activity of pepsin, which peaks at pH 2.0 and drops sharply from pH 4.0 to pH 6.0 (Fig. 1)11. As a reference, the dissolution rate of fibrin glue by acid without pepsin was also measured at the same pH levels. Preparation of artificial gastric juice with pepsin was prepared under different conditions of pH1.2, 2.0, 4.0, 5.5, and 6.0; these five groups in total were set up with reference to the activity of pepsin, which peaks at pH 2.0 and drops sharply from pH 4.0 to pH 6.0 (Fig. 1)11. As a reference, the dissolution rate of fibrin glue by acid without pepsin was also measured at the same pH levels. Preparation of artificial gastric juice with pepsin was prepared under adding 1,000 mL of water to 2.0 g of sodium chloride and 7.0 mL of 35% hydrochloric acid, according to the first solution of the JP Dissolution Test Method. In the pepsin-containing group, porcine gastric mucosa-derived pepsin (2,953 U per mg, BBI Solutions Ltd., Cardiff, United Kingdom) was added at 0.1%. The pH was adjusted using...
sodium hydroxide; hydrochloric acid was also used for fine adjustment. Artificial gastric juice (10 mL) was used for one sample (Fig. 2).

A locking mixer with a shaking condition of 8 rpm (RM-80, AS One Co., Ltd., Osaka, Japan) was installed in an incubator (LST-300D, TOKYO RIKAKIKAI CO, LTD., Tokyo, Japan) and set at 37 °C for the measurements. The mean number of remaining layers was measured every 30 min for the first 6 h, every 6 h until the third day, and every other day until the seventh day; the measurements were compared in three samples per group. As
fibrin dissolved, its degradation products and additives contained in the fibrin glue leached into the artificial gastric juice and raised the pH; therefore, the pH was adjusted after each measurement by manual addition of hydrochloric acid. The timing of layer dissolution, which was defined as the release of the PGA sheet into the artificial gastric juice after shaking the vial gently, was recorded (Fig. 3).

**Results**

All three layers of fibrin in all three samples with pepsin dissolved in 2 h in the pH 1.2 group, in 5 h in the pH 2.0 group, in 12 h in the pH 4.0 group, and in 48 h and 6 h in the pH 5.5 group (Figs. 4 and 5). In the pH 6.0 with pepsin group, fibrin was not dissolved at all, even after 168 h. In the pepsin-free groups, all three layers of samples disappeared completely after 72 h in the pH 1.2 group and after 96 h in the pH 2.0 group; in the pH 4.0 group (Fig. 6), fibrin was not dissolved at all even after 168 h.

**Discussion**

The present study showed that fibrin glue was dissolved by gastric acid, but its dissolution could be significantly prevented by controlling the pH level. Our results suggested that fibrin glue can be easily dissolved by gastric juice under low pH conditions. Although the activity of pepsin is the highest at pH 2.0 and is reduced to less than 30% at pH 1.2\(^{10}\), the relatively fast dissolution of fibrin in the pH 1.2 group was likely brought about by cleavage of the fibrin gel fibers by the strong acid itself. Dissolution of fibrin glue was more delayed in pH 4.0 than in pH 1.2 and 2.0, requiring 24 h for complete dissolution. Although 70% of pepsin activity remains at pH 4.0\(^{10}\), it was likely that the delay in dissolution was secondary to inhibition of protein cleavage by the acid. When the pH was raised to 5.5, pepsin activity dropped to below 10%\(^{10}\), and fibrin glue dissolution in all samples took 54 h. Moreover, at pH 6, the fibrin glue did not dissolve for 168 hours in any of the layers in all samples. These results implied the importance of keep the pH high to prevent fibrin dissolution in order to both counteract the effect of the acid and inhibit the activity of pepsin.

Vonoprazan is a potassium antagonist that has been shown to maintain an acid-blocking effect that is higher than that of the proton pump inhibitors esomeprazole and rabeprazole in healthy adult men; after a daily dose of 20 mg for seven days, it was found to have a retention rate of > 85% at pH 4 or higher for 24 h\(^{11}\). The other advantage of vonoprazan is that it provides maximal acid-inhibition from the first day of administration\(^{11}\), whereas PPIs require several doses and have a slower effect on gastric acid secretion, reaching a plateau in 3–5 days\(^{12,13}\). Some comparative studies on the treatment of artificial ulcers after ESD have shown that vonoprazan had a stronger acid-inhibiting effect than PPIs\(^{14,15}\). The use of vonoprazan may be effective in prolonging the adhesive effect of fibrin glue in the stomach.

However, the extent to which the use of vonoprazan affects delayed bleeding rates in practice is unknown. Tsuji et al. reported a successful reduction in the rate of delayed bleeding with this treatment despite the use of rabeprazole\(^{16}\). In our opinion, many factors determine the effectiveness of this treatment method, and control of intragastric pH is only one of them. Therefore, it is necessary to accumulate various innovations.
Although the combination of fibrin glue and PGA sheets has been used for a long time in the surgical field, its basic research and use in clinical practice in the field of gastrointestinal endoscopy had been few. When this strategy used during gastrointestinal endoscopy, it would be necessary to consider issues, such as limited manipulation through the forceps hole and the abundant amount of mucus and digestive juices in the operative field, compared with that in the surgical field. In previous basic experiments, PGA sheets exposed to highly viscous liquids, such as saliva and gastric mucus, was proven to prevent the adhesion of fibrin glue\textsuperscript{17,18}. To solve this problem, we developed and showed the usefulness of a delivery system for PGA sheets in the gastrointestinal tract.

Figure 4. Change in the mean number of the remaining layers in the pH 1.2 and pH 2.0 with pepsin groups over time (N = 3).

Figure 5. Change in the mean number of the remaining layers in the pH 4.0, pH 5.5, and pH 6.0 with pepsin groups over time (N = 3).
through animal experiments and excised pig stomach\(^{18-20}\). Based on this present study, we propose the use of a strong antacid agent to extend the effectiveness of fibrin glue in the gastrointestinal tract. Although accumulation of clinical experience is important, we believe that this additional basic study would strengthen the value of this technique in dealing with complications of gastrointestinal endoscopic procedures.

**Limitations**

The values shown in the results of this study are the averages of three samples from each group conducted in the exploratory research. The in vitro design of this study was less ideal for observing fibrin dissolution, compared with that of the actual environment in the stomach for two reasons. First, the constant immersion in artificial gastric acid and continuous shaking of fibrin gel resulted in uninterrupted exposure to acid and pepsin. Second, the absence of viscous components, such as mucin, in the artificial gastric acid made the fibrin gel highly permeable. Fukuda et al. reported that PGA sheets fixed with fibrin glue remained in the stomach for up to 32 days\(^{6}\); therefore, the results of the present study cannot be applied to clinical practice in the time period. In addition, in clinical practice, the fibrin glue should remain in the stomach longer because stomach acid is diluted by eating and drinking water. Care must be taken to not overestimate gastric acid dissolution of the fibrin glue. The actual impact on patients needs to be verified in clinical trials.

**Conclusions**

Keeping a near neutral pH in the stomach was important to prevent gastric acid dissolution of fibrin glue. Selection of a strong antacid may be effective in prolonging the duration of fibrin glue retention in the stomach.

**Data availability**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 6 October 2021; Accepted: 29 March 2022
Published online: 28 April 2022

**References**

1. Ono, H., Takizawa, K., Kakushima, N., Tanaka, M. & Kawata, N. Application of polyglycolic acid sheets for delayed perforation after endoscopic submucosal dissection of early gastric cancer. *Endoscopy* 47(Suppl 1), E18–E19 (2015).
2. Takimoto, K. & Hagiwara, A. Filling and shielding for postoperative gastric perforations of endoscopic submucosal perforations using endoscopic submucosal dissection using polyglycolic acid sheets and fibrin glue. *Endosc. Int. Open* 4, E661–E664 (2016).
3. Kawabata, H. *et al.* Endoscopic closure of an anastomo-cutaneous fistula: Filling and shielding using polyglycolic acid sheets and fibrin glue with easily deliverable technique. *Endosc. Int. Open* 6, E994–E997 (2018).
4. Nakano, Y. *et al.* Endoscopic plombage with polyglycolic acid sheets and fibrin glue for gastrointestinal fistulas. *Surg. Endosc.* 33, 1793–1801 (2019).
5. Kengo, T. *et al.* Efficacy of polyglycolic acid sheeting with fibrin glue for perforations related to gastrointestinal endoscopic procedures: A multicenter retrospective cohort study. *Surg Endosc.* (2021). [https://doi.org/10.1007/s00464-021-08873-5](https://doi.org/10.1007/s00464-021-08873-5). Online ahead of print.
6. Fukuda, H. et al. Polyglycolic acid felt sealing method for prevention of bleeding related to endoscopic submucosal dissection in patients taking antithrombotic agents. *Gastroenterol. Res. Pract.* **2016**, 1457357 (2016).
7. Kawata, N. et al. Efficacy of polyglycolic acid sheets and fibrin glue for prevention of bleeding after gastric endoscopic submucosal dissection in patients under continued antithrombotic agents. *Gastric Cancer* **21**, 696–702 (2018).
8. Kataoka, Y. et al. Endoscopic tissue shielding to prevent bleeding after endoscopic submucosal dissection: A prospective multicenter randomized controlled trial. *Endoscopy* **51**, 619–627 (2019).
9. Nonaka, S. et al. The management of gastrointestinal stenosis after wide-range ESD for early gastric cancer. *Gastroenterol. Endosc.* **25**, 721–728 (2013) (in Japanese).
10. Piper, D. W. & Fenton, B. H. pH stability and activity curves of pepsin with special reference to their clinical importance. *Gut* **6**, 506–508 (1965).
11. Sakurai, Y. et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study. *Aliment. Pharmacol. Ther.* **42**, 719–730 (2015).
12. Junghard, O. et al. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. *Eur. J. Clin. Pharmacol.* **58**, 453–458 (2002).
13. Mejia, A. et al. Acid peptic diseases: Pharmacological approach to treatment. *Expert Rev. Clin. Pharmacol.* **2**, 295–314 (2009).
14. Maruoka, D. et al. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score-matching analysis. *Dig Endosc.* **29**(1), 57–64 (2017).
15. Kagawa, T. et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. *Aliment Pharmacol. Ther.* **44**(6), 583–591 (2016).
16. Tsuji, Y. et al. Polyglycolic acid sheets and fibrin glue decrease the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms (with video). *Gastrointest Endosc.* **81**(4), 906–912 (2015).
17. Takagawa, Y., Takao, T. & Ono, H. Fundamental examination into the use of fibrin glue and polyglycolic acid sheets as a method for covering post-ESD ulcers. *Gastroenterol. Endosc.* **57**, 1150–1157 (2015) (in Japanese).
18. Takao, T. et al. Tissue shielding with polyglycolic acid sheets and fibrin glue on ulcers induced by endoscopic submucosal dissection in a porcine model. *Endosc. Int. Open* **3**, E146–E151 (2015).
19. Takao, T. et al. A novel and effective delivery method for polyglycolic acid sheets to post-endoscopic submucosal dissection ulcers. *Endoscopy* **49**, 359–364 (2017).
20. Sakaguchi, H. et al. Efficacy of the envelope method in applying polyglycolic acid sheets to post-endoscopic submucosal dissection ulcers in living pigs. *Clin. Endosc.* **54**, 64–72 (2021).

**Author contributions**

Y.T., T. Takao: conception and design of the study, literature research and writing of the manuscript. H.S., T.N.: assisted in the design of the study and revision of the manuscript. Y.T., K.T.: derived the models and analyzed the data. Y.T.: performed the measurements. K.T.: assisted with the measurements. Y.M., T. Toyonaga, Y.K.: involved in planning and supervising the work. The author(s) read and approved the final manuscript.

**Competing interests**

Mr. Takegawa and Mr. Takeo are employees of KM Biologics Co., Ltd. and the fibrin glue (BOLHEAL®) used in this article is manufactured by KM Biologics Co., Ltd. Dr. Takao, Dr. Sakaguchi, Dr. Nakai, Dr. Morita, Dr. Toyonaga, and Dr. Kodama have no conflict of interest.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-10968-5.

**Correspondence** and requests for materials should be addressed to T.T.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022